Calidi Biotherapeutics Statistics
Share Statistics
Calidi Biotherapeutics has 18.85M shares outstanding. The number of shares has increased by -46.97% in one year.
| Shares Outstanding | 18.85M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 133.14% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 16.77M |
| Failed to Deliver (FTD) Shares | 11.14K |
| FTD / Avg. Volume | 0.66% |
Short Selling Information
The latest short interest is 585.63K, so 3.11% of the outstanding shares have been sold short.
| Short Interest | 585.63K |
| Short % of Shares Out | 3.11% |
| Short % of Float | 3.49% |
| Short Ratio (days to cover) | 0.88 |
Valuation Ratios
The PE ratio is -8.32 and the forward PE ratio is -2.34.
| PE Ratio | -8.32 |
| Forward PE | -2.34 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -29.53 |
| P/FCF Ratio | -8.82 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Calidi Biotherapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.42, with a Debt / Equity ratio of -0.35.
| Current Ratio | 0.42 |
| Quick Ratio | 0.42 |
| Debt / Equity | -0.35 |
| Total Debt / Capitalization | -53.41 |
| Cash Flow / Debt | -9.41 |
| Interest Coverage | -27.12 |
Financial Efficiency
Return on equity (ROE) is 3.55% and return on capital (ROIC) is 2903.69%.
| Return on Equity (ROE) | 3.55% |
| Return on Assets (ROA) | -2.92% |
| Return on Capital (ROIC) | 2903.69% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -712.59K |
| Employee Count | 41 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 16.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -91.71% in the last 52 weeks. The beta is 0.57, so Calidi Biotherapeutics 's price volatility has been higher than the market average.
| Beta | 0.57 |
| 52-Week Price Change | -91.71% |
| 50-Day Moving Average | 1.7 |
| 200-Day Moving Average | 2.02 |
| Relative Strength Index (RSI) | 36.1 |
| Average Volume (20 Days) | 1.70M |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.26M |
| Operating Income | -28.99M |
| Net Income | -29.22M |
| EBITDA | -27.58M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.73 |
Balance Sheet
The company has 2.05M in cash and 7.24M in debt, giving a net cash position of -5.19M.
| Cash & Cash Equivalents | 2.05M |
| Total Debt | 7.24M |
| Net Cash | -5.19M |
| Retained Earnings | -99.57M |
| Total Assets | 6.66M |
| Working Capital | -9.36M |
Cash Flow
In the last 12 months, operating cash flow was -26.98M and capital expenditures -585.00K, giving a free cash flow of -27.57M.
| Operating Cash Flow | -26.98M |
| Capital Expenditures | -585.00K |
| Free Cash Flow | -27.57M |
| FCF Per Share | -1.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLDI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -142.98% |
| FCF Yield | -120.88% |
Analyst Forecast
The average price target for CLDI is $20, which is 1552.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 1552.9% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jul 15, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 15, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -37.99 |
| Piotroski F-Score | 0 |